Sounds eerily like cydy and its ICI tack. And I gu
Post# of 158771
(Total Views: 729)
Posted On: 11/19/2025 7:57:14 AM
Sounds eerily like cydy and its ICI tack. And I guess there are multiple others researching along the same lines as cydy. But they seem to be further behind cydy. Here is a quote from their PR.
"The program will initially target advanced breast cancer and non-small cell lung cancer (NSCLC), where PD-1/PD-L1 immunotherapies are widely used but resistance remains common. IND-enabling studies are expected to commence within six months, with a goal of initiating first-in-human studies within approximately 15 months."
Net, net, I would say that this is another good news confirmation of cydy's MoA and ICI plans than a sign of meaningful competition.
"The program will initially target advanced breast cancer and non-small cell lung cancer (NSCLC), where PD-1/PD-L1 immunotherapies are widely used but resistance remains common. IND-enabling studies are expected to commence within six months, with a goal of initiating first-in-human studies within approximately 15 months."
Net, net, I would say that this is another good news confirmation of cydy's MoA and ICI plans than a sign of meaningful competition.
(12)
(0)